•HashKey Middle East launched Bitcoin and Ethereum perpetual derivatives following regulatory approval from Dubai's Virtual Assets Regulatory Authority (VARA).
•Agios Pharmaceuticals announced that Phase 2 results for tebapivat did not establish a differentiated profile to support continued development in sickle cell disease.
•The FDA has set a PDUFA goal date of November 1, 2026, for the company's other drug, mitapivat, in sickle cell disease.